Patents Represented by Attorney Kalow & Springut LLP
  • Patent number: 8030474
    Abstract: Efficient sequence specific gene silencing for cyclin-dependent kinase 4 is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: October 4, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 8030476
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CKSF1B1.
    Type: Grant
    Filed: April 7, 2010
    Date of Patent: October 4, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 8026349
    Abstract: Methods and compositions for making nucleoside phosphoramidites and nucleic acids, including mono-, di-, and polynucleotides, comprising a linker covalently attached to a levulinyl moiety are provided. A levulinyl-protected linking moiety affords an orthogonal approach to modifying a polynucleotide during or after solid phase synthesis with a molecule of interest, for example, a conjugate or a dye.
    Type: Grant
    Filed: August 18, 2005
    Date of Patent: September 27, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Stephanie A. Hartsel, Robert J. Kaiser, Michael O. Delaney
  • Patent number: 8022199
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MYD88.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: September 20, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 8022198
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: September 20, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 8013145
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: September 6, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 8008474
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs directed to silencing KRAS, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: August 30, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
  • Patent number: 8003075
    Abstract: The present invention includes a diagnostic assay for the detection and determination of MGP in a human serum sample, which comprises the use of one or more antibodies, preferably monoclonal antibodies, specifically recognizing epitopes on and/or conformations of human Matrix Gla-Protein. A method is provided for using MGP-related antigens as biomarkers for certain diseases, for example, atherosclerosis and other vascular diseases, and angiogenesis/neogenesis in tumor development. Monoclonal antibodies of class IgG are described for use in the assay, which are defined herein as mAb3-15, mAb35-49[Glu], mAb35-49[Gla], mAb35-53[Glu], and mAb35-53[Gla]. Polyclonal antibodies and methods are also disclosed for measuring MGP in a human serum sample.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: August 23, 2011
    Assignee: MGP Diagnostics A/S
    Inventor: Cees Vermeer
  • Patent number: 7999097
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for BACE.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: August 16, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 8000902
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: August 16, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 7991624
    Abstract: A method of obtaining information in a specific area from at least two persons having a defined level of knowledge in that specific area. A host, upon receiving a question for information, operates a web site platform for the exchange of information using the web site to send the question to each of the at least two persons for a response together with a suggested fee for a response to the question. Where the fee is not precisely fixed and at least one response to the question is received via the web site, a value is determined by subscribers to the website.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: August 2, 2011
    Assignee: Article One Partners Holdings
    Inventor: Cheryl Malone
  • Patent number: 7985854
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TAF1.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: July 26, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: D641957
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: July 26, 2011
    Assignee: The New York Hospital Medical Center of Queens
    Inventor: Terence Michael Brady
  • Patent number: D642074
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: July 26, 2011
    Assignee: Cartier Creation Studio SA
    Inventor: Arnaud Chastaingt
  • Patent number: D642076
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: July 26, 2011
    Assignee: Cartier Creation Studio SA
    Inventor: Arnaud Chastaingt
  • Patent number: D642490
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: August 2, 2011
    Assignee: Ralph Lauren Watch and Jewelry Company Sarl
    Inventor: Giampiero Bodino
  • Patent number: D643211
    Type: Grant
    Filed: February 2, 2010
    Date of Patent: August 16, 2011
    Assignee: Cartier Creation Studio SA
    Inventor: Marlin Yuson
  • Patent number: D643247
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: August 16, 2011
    Assignee: Mr. Bar-B-Q, Inc.
    Inventor: Marc Zemel
  • Patent number: D643325
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: August 16, 2011
    Assignee: Cartier Creation Studio SA
    Inventor: VĂ©ronique Marchand
  • Patent number: D644951
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: September 13, 2011
    Assignee: Cartier Creation Studio SA
    Inventor: Luca Iacomucci